HeartBeam Inc. (NASDAQ: BEAT), a medical technology company developing advanced cardiac monitoring solutions, has completed patient enrollment ahead of schedule in its HEADSTART-ACS study at the National Cardiovascular Center Harapan Kita in Jakarta, Indonesia. The study enrolled 486 patients to evaluate the diagnostic accuracy of the HeartBeam System in detecting acute coronary syndrome (ACS), including heart attacks, by comparing its three-dimensional electrocardiogram (ECG) technology with standard 12-lead ECGs. The early completion of enrollment is significant because it accelerates the timeline for data analysis, with results expected to be presented at a cardiology conference in 2027. This milestone brings HeartBeam closer to potentially offering a portable, credit card-sized device that could transform cardiac care by enabling ECG monitoring outside traditional medical facilities.
The HEADSTART-ACS study is part of HeartBeam's broader clinical program. Combined with the 132-patient ALIGN-ACS pilot study, the company has now enrolled more than 600 patients across its heart attack detection studies. This cumulative experience is intended to support preparations for a pivotal U.S. study planned for the first quarter of 2027. The ability to enroll patients quickly in Indonesia may also position HeartBeam to explore deployment of its technology across community health centers in that country, potentially addressing unmet needs in underserved regions. For investors, the early enrollment completion reduces development risk and signals operational efficiency. As noted in the full press release available at https://ibn.fm/1c6Br, the company is making steady progress toward regulatory submission.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. The HeartBeam System is not currently cleared for heart attack detection, and its use in both studies remains investigational. However, the completion of enrollment in HEADSTART-ACS represents a critical step in generating the clinical evidence needed for future regulatory filings. The company's focus on developing a cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG could redefine cardiac health management by allowing physicians to identify cardiac trends and acute conditions remotely. For more details on the company's cleared indications, refer to https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
The announcement comes as HeartBeam seeks to differentiate itself in the cardiac monitoring market. With the global burden of cardiovascular disease rising, portable and accurate diagnostic tools are in high demand. The successful completion of this study enrollment not only validates the company's clinical trial infrastructure but also enhances its credibility with partners and regulators. As HeartBeam prepares for its pivotal U.S. study, the data from HEADSTART-ACS will be closely watched by clinicians and investors alike. The company's progress is being tracked by BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. For a full view of the announcement, visit the press release at https://ibn.fm/1c6Br.
